查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1629873

全球呼吸護理設備市場 - 2025-2033

Global Respiratory Care Devices Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2023年，全球呼吸護理設備市場規模達228.5億美元，預計2033年將達到405.9億美元，2025-2033年預測期間複合年成長率為6.4%。

呼吸照護裝置是用於支持和改善呼吸困難或肺部相關疾病患者的呼吸功能的醫療設備。它們用於預防、診斷、監測和治療氣喘、慢性阻塞性肺病、睡眠呼吸中止症和急性呼吸窘迫症候群等呼吸系統疾病。主要類型包括呼吸器等治療設備、肺活量計等診斷工具、脈搏血氧儀等監測設備。這些設備廣泛應用於醫院、診所和家庭護理場所，以改善患者的治療效果和生活品質。

市場動態：

驅動程式和限制

呼吸道疾病盛行率上升

全球呼吸照護設備市場是由慢性阻塞性肺病、氣喘、睡眠呼吸中止症和急性感染等呼吸系統疾病的增加所推動的。空氣污染、吸煙和人口老化等因素導致了這些狀況。這些疾病需要長期管理和先進的醫療支援。 COVID-19 大流行凸顯了呼吸護理設備在管理急性呼吸窘迫方面的重要性，從而提高了人們的意識和投資。呼吸系統疾病負擔的增加鼓勵了攜帶式、方便用戶使用型設備的創新，迎合了家庭護理的趨勢。這種流行加速了市場成長，並強調了全球對可獲得、高效且負擔得起的呼吸護理解決方案的需求。

例如，根據非傳染性疾病聯盟的說法，慢性呼吸道疾病 (CRD) 是一種與肺部相關的疾病，在全世界造成顯著的發病率和死亡率。常見的 CRD 包括慢性阻塞性肺病 (COPD)、氣喘、肺癌和職業性肺病。這些疾病影響全球至少 5,500 億成年人，佔所有死亡人數的 7%。肺癌每年導致另外 14 億人死亡。五歲以下兒童特別容易受到肺部疾病的影響，包括肺炎等急性傳染病和氣喘等慢性疾病。氣喘是最常見的慢性病，​​影響全球 14% 的兒童。 1990 年至 2017 年間，CRD 的盛行率增加了 40%，但與其他非傳染性疾病相比，它們受到較少的關注。

設備操作的複雜性

由於設備操作的複雜性，特別是呼吸器、CPAP 機和製氧機等先進設備，全球呼吸護理設備市場面臨嚴重限制。這些設備需要專業知識才能正確設置、使用和維護，由於對家庭護理環境中的醫療保健專業人員、護理人員和患者的培訓不足，這可能具有挑戰性。

這項挑戰在醫療保健專業人員可能缺乏專業知識且家庭醫療保健環境往往缺乏適當支持的資源匱乏地區更為明顯。對監控和校準的持續需求增加了複雜性，需要熟練的勞動力來確保最佳的設備功能。這些操作困難可能會阻礙呼吸護理設備的採用，特別是在服務不足的地區，從而限制了市場的成長潛力。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 呼吸道疾病盛行率上升
    • 限制
      • 設備操作的複雜性
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析

第 6 章：依產品類型

  • 治療設備
    • 持續性呼吸道正壓通氣 (CPAP) 設備
    • 雙水平氣道正壓通氣 (BiPAP) 裝置
    • 呼吸器
    • 霧化器
    • 吸入器（定量吸入器、乾粉吸入器）
    • 制氧機
  • 監控設備
    • 脈搏血氧儀
    • 二氧化碳描記器
    • 氣體分析儀
  • 診斷設備
    • 肺活量計
    • 多導睡眠監測設備
    • 峰值流量計
  • 耗材及配件
    • 呼吸迴路
    • 鼻插管
    • 面具
    • 管
    • 過濾器

第 7 章：按申請

  • 慢性阻塞性肺病（COPD）
  • 氣喘
  • 阻塞性睡眠呼吸中止症 (OSA)
  • 呼吸窘迫症候群
  • 其他

第 8 章：最終用戶

  • 醫院和診所
  • 家庭護理設置
  • 門診手術中心

第 9 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 10 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 11 章：公司簡介

  • Philips Respironics (Philips Healthcare)
    • 公司概況
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • ResMed Inc.
  • Medtronic Plc
  • Fisher & Paykel Healthcare
  • Invacare Corporation
  • Dragerwerk AG & Co. KGaA
  • GE Healthcare
  • Getinge AB
  • Teleflex Incorporated
  • Hamilton Medical AG

第 12 章：附錄

簡介目錄
Product Code: MD8903

The global respiratory care devices market reached US$ 22.85 billion in 2023 and is expected to reach US$ 40.59 billion by 2033, growing at a CAGR of 6.4% during the forecast period 2025-2033.

Respiratory care devices are medical equipment used to support and improve the respiratory functions of patients with breathing difficulties or lung-related conditions. They are used for the prevention, diagnosis, monitoring, and treatment of respiratory disorders like asthma, COPD, sleep apnea, and ARDS. Key types include therapeutic devices like ventilators, diagnostic tools like spirometers, and monitoring devices like pulse oximeters. These devices are widely used in hospitals, clinics, and home care settings to improve patient outcomes and quality of life.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Respiratory Diseases

The global respiratory care devices market is driven by the rise in respiratory diseases like COPD, asthma, sleep apnea, and acute infections. Factors like air pollution, smoking, and aging populations contribute to these conditions. Long-term management and advanced medical support are needed for these diseases. The COVID-19 pandemic highlighted the importance of respiratory care devices in managing acute respiratory distress, leading to increased awareness and investment. The rising burden of respiratory diseases has encouraged innovation in portable, user-friendly devices, catering to home-based care trends. This prevalence accelerates market growth and emphasizes the need for accessible, efficient, and affordable respiratory care solutions globally.

For instance, according to NCD Alliance, Chronic respiratory diseases (CRDs) are lung-related diseases that cause significant morbidity and mortality worldwide. Common CRDs include COPD, asthma, lung cancer, and occupational lung diseases. These diseases affect at least 550 Billion adults globally and account for 7% of all deaths. Lung cancer contributes to another 1.4 Billion deaths annually. Children under five years of age are particularly affected by lung diseases, including acute infectious diseases like pneumonia and chronic conditions like asthma. Asthma is the most common chronic condition, affecting 14% of children globally. The prevalence of CRDs has increased by 40% between 1990 and 2017, but they have received less attention than other NCDs.

Complexity of Device Operation

The global respiratory care devices market faces significant restraint due to the complexity of device operation, especially advanced devices like ventilators, CPAP machines, and oxygen concentrators. These devices require specialized knowledge for proper setup, usage, and maintenance, which can be challenging due to inadequate training for healthcare professionals, caregivers, and patients in home care settings.

This challenge is more pronounced in low-resource regions where healthcare professionals may lack expertise, and home healthcare settings often lack proper support. The constant need for monitoring and calibration adds to the complexity, requiring a skilled workforce to ensure optimal device functionality. These operational difficulties can discourage the adoption of respiratory care devices, especially in underserved areas, limiting the market's growth potential.

Segment Analysis

The global respiratory care devices market is segmented based on product type, application, end user and region.

Product type:

Therapeutic Devices segment is expected to dominate the respiratory care devices market share

The therapeutic devices segment holds a major portion of the respiratory care devices market share and is expected to continue to hold a significant portion of the respiratory care devices market share during the forecast period.

Therapeutic devices are crucial in managing chronic and acute respiratory conditions, such as COPD, asthma, sleep apnea, and respiratory distress syndrome. The global respiratory care devices market is growing due to factors like air pollution, smoking, and aging populations. Technological advancements, such as portable oxygen concentrators and smart CPAP machines, have enhanced patient convenience and compliance. The COVID-19 pandemic highlighted the importance of ventilators and oxygen therapy, leading to increased awareness and investment in therapeutic devices. The trend towards home-based care and reducing healthcare costs has driven the adoption of these devices, ensuring long-term management of respiratory diseases outside traditional healthcare settings.

For instance, in September 2024, ResMed has launched its AirTouch N30i continuous positive airway pressure (CPAP) mask, designed to provide a comfortable sleep experience for users with sleep apnea. The mask features a fabric-wrapped frame and a soft, breathable, moisture-wicking design for optimal comfort. It builds upon ResMed's previous masks to combine softness, breathability, and a high-performance seal, making it easier for people to start and stick with CPAP therapy.

Moreover, in February 2024, ResMed has introduced its AirCurve 11 series, a bilevel device that uses inspiratory and expiratory positive airway pressure (IPAP) to treat sleep apnea. The AirCurve 11 VAuto is a bilevel PAP that provides higher pressure during inhalation and lower pressure during exhalation, allowing the device to align more closely with natural breathing patterns.

Application:

Chronic Obstructive Pulmonary Disease (COPD) segment is the fastest-growing segment in respiratory care devices market share

The Chronic Obstructive Pulmonary Disease (COPD) segment is the fastest-growing segment in the respiratory care devices market share and is expected to hold the market share over the forecast period.

Chronic Obstructive Pulmonary Disease (COPD) is a major global health concern, causing significant morbidity and mortality. The condition, primarily caused by smoking, air pollution, occupational hazards, and genetic factors, has led to a surge in demand for respiratory care devices like oxygen concentrators, nebulizers, and ventilators. These devices are crucial for managing symptoms, improving oxygenation, and enhancing patient quality of life. The growing awareness of early diagnosis and treatment, coupled with technological advancements, has fueled the adoption of portable and home-based solutions for COPD management. The economic burden of hospitalizations due to severe COPD exacerbations has shifted focus towards preventive and long-term care, driving market expansion globally.

For instance, in March 2023, Pulmonologists at the University of Cincinnati have developed a new breathing device called PEP Buddy, which not only improves breathlessness and quality of life for COPD patients but also benefits those dealing with stress and anxiety, as well as those practicing mindfulness, meditation, or yoga. The device, created by Muhammad Ahsan Zafar and Ralph Panos, was published in the journal Respiratory Care. Zafar is an associate professor in the Department of Pulmonary Critical Care and Sleep Medicine, Panos is a professor emeritus in pulmonary and critical care.

Geographical Analysis

North America is expected to hold a significant position in the respiratory care devices market share

North America holds a substantial position in the respiratory care devices market and is expected to hold most of the market share due to the novel product launches, high prevalence of chronic diseases like COPD, asthma, and sleep apnea, driven by lifestyle factors and an aging population. The region's healthcare infrastructure supports the widespread use of advanced respiratory care devices, such as ventilators, nebulizers, and CPAP machines. Government and private insurance programs offer favorable reimbursement policies, reducing financial burdens and enabling broader access. The region is also a hub for innovation, with companies investing in portable, wireless, and AI-powered devices for home-based care.

For instance, in December 2024, University Medical Devices (UMD) has launched its first specimen collection method, MicroWash, a comfortable and sensitive nasal lavage device designed as a less invasive alternative to nasal swabs during the COVID-19 pandemic.

Moreover, in July 2023, Emerson has introduced the ASCO Series 588 Stationary Oxygen Concentrator Manifold, a turnkey solution for the healthcare industry. This manifold optimizes respiratory therapy device designs, accelerates product speed to market, and improves energy efficiency, lifespan, and reliability of oxygen concentrators, ensuring they are readily available and reliable for patients.

Europe is growing at the fastest pace in the respiratory care devices market

Europe holds the fastest pace in the respiratory care devices market and is expected to hold most of the market share due to the aging population, environmental factors, and the healthcare system's focus on early diagnosis and treatment. The adoption of novel advanced respiratory care devices is encouraged by reimbursement frameworks and the growing trend towards home-based care solutions. Countries like Germany, France, and the UK drive innovation and market growth due to their strong clinical research capabilities and supportive regulatory environments.

For instance, in October 2024, Chiesi UK and Ireland and Health Innovation Manchester have launched the iMprovIng outcomes in respiratory care Greater Manchester (MISSON) project, which will introduce clinically-validated LungHealth software to up to 150 GP practices in Greater Manchester over a two-year period. The software uses digital technology, embedded algorithms, and patient medical records to provide computer-guided consultations for asthma and COPD annual reviews.

Moreover, in October 2024, The LungHealth software, developed by Health Innovation Manchester and Chiesi UK and Ireland, is being introduced to 150 GP practices in Greater Manchester over a two-year period. The software uses embedded algorithms and patients' medical records to provide computer-guided consultations for asthma and COPD annual reviews. The software can be carried out remotely or face-to-face, and also provides clinical prompts to upskill healthcare professionals. The MISSION project aims to evaluate the technology's effectiveness in improving the quality, effectiveness, and consistency of reviews, thereby reducing the impact of asthma and COPD exacerbations on patients and the NHS.

Competitive Landscape

The major global players in the respiratory care devices market include Koninklijke Philips N.V.; Fitbit (Google); Garmin Ltd.; Medtronic; Omron; Withings; VitalConnect; Polar Electro; Sotera, Inc.; INVIZA Corporation; Dexcom, Inc.; GE HealthCare; CONTEC MEDICAL SYSTEMS CO., LTD; Nanowear Inc. among others.

Emerging Players

The emerging players in the respiratory care devices market include Vivos Therapeutics, Omron Healthcare, AirSep Corporation and among others.

Key Developments

  • In February 2024, Getinge, a global medical technology leader, has introduced the Servo-c mechanical ventilator, a revolutionary device designed to address the diverse respiratory needs of patients in India, both pediatric and adult. The ventilator is designed to provide lung-protective therapeutic tools, catering to the evolving healthcare landscape. Getinge aims to empower hospitals with advanced healthcare solutions without compromising on quality, focusing on accessibility and affordability.
  • In March 2023, Vitalograph, a respiratory diagnostic device developer, has launched its VitaloPFT Pulmonary Function Testing Series for secondary care use. The launch took place at the Arab Health Exhibition in Dubai, supported by Irish minister for trade promotion and digital transformation Dara Calleary TD and Irish ambassador Alison Milton. The VitaloPFT Series provides advanced respiratory diagnostic solutions for hospitals and other secondary care units requiring complex pulmonary function testing.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global respiratory care devices market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Component & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Application
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the Prevalence of Respiratory Diseases
    • 4.1.2. Restraints
      • 4.1.2.1. Complexity of Device Operation
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. By Product type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product type
    • 6.1.2. Market Attractiveness Index, By Product type
  • 6.2. Therapeutic Devices*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 6.2.3. Continuous Positive Airway Pressure (CPAP) Devices
    • 6.2.4. Bi-level Positive Airway Pressure (BiPAP) Devices
    • 6.2.5. Ventilators
    • 6.2.6. Nebulizers
    • 6.2.7. Inhalers (Metered-Dose Inhalers, Dry Powder Inhalers)
    • 6.2.8. Oxygen Concentrators
  • 6.3. Monitoring Devices
    • 6.3.1. Pulse Oximeters
    • 6.3.2. Capnographs
    • 6.3.3. Gas Analyzers
  • 6.4. Diagnostic Devices
    • 6.4.1. Spirometers
    • 6.4.2. Polysomnography Devices
    • 6.4.3. Peak Flow Meters
  • 6.5. Consumables and Accessories
    • 6.5.1. Breathing Circuits
    • 6.5.2. Nasal Cannulas
    • 6.5.3. Masks
    • 6.5.4. Tubes
    • 6.5.5. Filters

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application
  • 7.2. Chronic Obstructive Pulmonary Disease (COPD)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Asthma
  • 7.4. Obstructive Sleep Apnea (OSA)
  • 7.5. Respiratory Distress Syndrome
  • 7.6. Others

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Hospitals & Clinics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Home Care Settings
  • 8.4. Ambulatory Surgical Centers

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Spain
      • 9.3.6.5. Italy
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Philips Respironics (Philips Healthcare)*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. ResMed Inc.
  • 11.3. Medtronic Plc
  • 11.4. Fisher & Paykel Healthcare
  • 11.5. Invacare Corporation
  • 11.6. Dragerwerk AG & Co. KGaA
  • 11.7. GE Healthcare
  • 11.8. Getinge AB
  • 11.9. Teleflex Incorporated
  • 11.10. Hamilton Medical AG

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1 About Us and Services
  • 12.2 Contact Us